Chapter title |
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment
|
---|---|
Chapter number | 16 |
Book title |
Plasma Cell Dyscrasias
|
Published in |
Cancer treatment and research, January 2016
|
DOI | 10.1007/978-3-319-40320-5_16 |
Pubmed ID | |
Book ISBNs |
978-3-31-940318-2, 978-3-31-940320-5
|
Authors |
Prashant Kapoor, Stephen M. Ansell, Esteban Braggio, Kapoor, Prashant, Ansell, Stephen M., Braggio, Esteban |
Abstract |
Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 9% |
Unknown | 10 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 2 | 18% |
Student > Ph. D. Student | 2 | 18% |
Student > Master | 2 | 18% |
Student > Doctoral Student | 1 | 9% |
Researcher | 1 | 9% |
Other | 2 | 18% |
Unknown | 1 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 27% |
Agricultural and Biological Sciences | 2 | 18% |
Biochemistry, Genetics and Molecular Biology | 1 | 9% |
Computer Science | 1 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Other | 0 | 0% |
Unknown | 3 | 27% |